Cambridge, UK, 07 January: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, is pleased to confirm that its PROFILE trial has reached the half way mark in terms of recruitment, having secured over 200 patients.
Funded by Wellcome Trust as part of its translational grant award funding stream, the PROFILE trial is the first biomarker stratified study for Crohn’s disease and potentially immune-mediated diseases as a whole. The trial seeks to demonstrate that stratifying…
DUBLIN, Ireland, and Ipswich MA, USA, 07 January 2020: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with New England Biolabs (NEB®), a global leader in the discovery and production of enzymes for molecular biology applications, granting NEB rights to sell CRISPR/Cas9 tools and reagents.
NEB offers the largest selection of recombinant and native enzymes for genomic research, and continues to expand its product offerings into new areas…
Cambridge, UK, 07 January 2020: PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a multi-project drug discovery collaboration with Boehringer Ingelheim, one of the world-leading pharmaceutical companies developing innovative therapies for diseases with unsatisfactory treatments. Under the terms of the agreement, PhoreMost will receive an upfront payment and research funding together with downstream success-based milestones. Further financial terms are not disclosed.
PhoreMost will deploy its in-…
Cambridge 06 January 2020: Sponsors of the Babraham Research Campus Accelerate@Babraham initiative, LifeArc, has announced the extension of its support, by releasing an additional £10,000 in the form of an award for the most progressed venture currently participating in the StartUPCompetition@Babraham 2019/20 programme.
Introduced by the Babraham Research Campus in 2018, the Accelerate@Babraham initiative is designed to support ambitious early stage life science ventures within the active Babraham Research Campus community. It does this by giving access to appropriate short-term open…
Viral vectors have taken a striking importance in the current biomanufacturing landscape, with the unprecedented global need for viral particles creating significant capacity and productivity challenges.
Join our educational webinar and learn how recent innovation can help you to significantly push the boundaries of viral vectors productivity and quality.
Discover how recent innovation in areas such as cells, media and transfection agents can boost and standardise your process, as illustrated by our lentiviral case study. Get updates about recent innovations in both benchtop and production…
AMSBIO has expanded its range of cfPure™ Cell Free DNA Purification Kits for rapid and efficient isolation of circulating cell free DNA (cfDNA). A new cfPure™Max kit is now available for use on samples of 5mLs volume or greater.AMSBIO cfPure® kits use silica-coated paramagnetic particles to purify cell free DNA from less than 1 mL to greater than 10 mL of serum or plasma. The buffers were developed to ensure efficient recovery of 100 bp – 500 bp DNA fragments in order to maximize recovery of cell free DNA. The recovered DNA is suitable for a wide range of down-…
Cambridge, UK, – 17 December 2019: Abcam plc, a global innovator in life science reagents and tools, and SomaServe Ltd, a Pharma service and specialist reagent business exploiting PolyNautâ Technology, have announced a partnership to commercialise the cell delivery potential of the polymer-based ‘bionic’ nanoparticles, which can carry a range of payloads directly to live cells.
Dr Fran Crawford, CEO, SomaServe, commented: “Abcam’s reputation as an innovator in the field of biological reagents and dedicated global commercialisation infrastructure, coupled with their transparent and collegiate…
Westbury, NY – Dec. 16, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today launched its Next-generation Sequencing (NGS) Service, which combines the company’s expertise in human tissue procurement, specimen selection, sample preparation and project management with its in-house NGS capabilities. BioIVT now offers both standard and custom NGS services, including sample extraction, library preparation, sequencing and bioinformatics.
“We are excited to launch our NGS Service to support researchers investigating the human genome to…
The UK Innovation Corridor has a unique ecosystem of talent and commerce, with world-class businesses, universities and R&D centres standing firmly on a heritage of ground-breaking discovery and invention, as shown by a new report released today at the Genesis Conference by the London Stansted Cambridge Consortium.
This makes it the perfect place to start and build an innovation company and invest in place-making.
Three dynamic factors have led to continued investment and start-ups by innovative technology-based companies, as well as significant commercial real estate investments in…
Start Codon cohort companies to receive One Nucleus membership benefits
CAMBRIDGE, UK, 11 December 2019 – Start Codon, a new model of life science and healthcare business accelerator, today announced it has partnered with One Nucleus, a membership organisation for life science and healthcare companies. Under the terms of the partnership agreement, One Nucleus will support and profile the life science and healthcare start-ups participating in the Start Codon accelerator programme.
Founded in April 2019, Start Codon aims to identify and recruit high potential life science and healthcare…